Eupraxia Pharmaceuticals Inc
EPRX8.350USD
-0.110-1.30%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
422.50MMarket Cap
LossP/E TTM
More Details of Eupraxia Pharmaceuticals Inc Company
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc Info
Ticker SymbolEPRX
Company nameEupraxia Pharmaceuticals Inc
IPO dateMar 09, 2021
CEOHelliwell (James A)
Number of employees33
Security typeOrdinary Share
Fiscal year-endMar 09
Address201-2067 Cadboro Bay Rd.
CityVICTORIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV8R 5G4
Phone12505903968
Websitehttps://eupraxiapharma.com/home/default.aspx
Ticker SymbolEPRX
IPO dateMar 09, 2021
CEOHelliwell (James A)
Company Executives of Eupraxia Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+3363.00%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
16.39K
+2465.00%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+3363.00%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
16.39K
+2465.00%
Dr. James A. Helliwell, M.D.
Dr. James A. Helliwell, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Manchester Management Company, L.L.C.
10.71%
Beutel, Goodman & Company Ltd.
7.81%
Disbrow (Robert)
6.48%
Freedman (Joseph S)
3.99%
Montalbano (John S.)
2.96%
Other
68.04%
Shareholders
Shareholders
Proportion
Manchester Management Company, L.L.C.
10.71%
Beutel, Goodman & Company Ltd.
7.81%
Disbrow (Robert)
6.48%
Freedman (Joseph S)
3.99%
Montalbano (John S.)
2.96%
Other
68.04%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.44%
Individual Investor
17.72%
Investment Advisor
10.59%
Venture Capital
4.33%
Research Firm
2.70%
Investment Advisor/Hedge Fund
0.86%
Other
45.34%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
2.42M
4.29%
--
2025Q3
25
2.42M
4.29%
+50.65K
2025Q2
23
2.37M
6.13%
+179.23K
2025Q1
19
2.20M
5.41%
+276.41K
2024Q4
17
1.89M
5.38%
+22.30K
2024Q3
16
6.03M
9.48%
+71.78K
2024Q2
12
5.96M
4.63%
+4.51M
2024Q1
3
1.45M
6.20%
-759.20K
2023Q4
4
4.37M
8.10%
--
2023Q3
4
4.37M
9.24%
--
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Manchester Management Company, L.L.C.
5.56M
10.98%
+2.78M
+99.82%
Dec 31, 2024
Beutel, Goodman & Company Ltd.
4.06M
8.01%
+4.06M
--
Sep 30, 2025
Disbrow (Robert)
3.37M
6.65%
+475.65K
+16.44%
Sep 30, 2025
Freedman (Joseph S)
2.07M
4.09%
+561.53K
+37.16%
Sep 26, 2025
Montalbano (John S.)
1.29M
2.55%
+12.50K
+0.98%
Nov 14, 2025
Vivo Capital, LLC
1.35M
2.67%
+1.35M
--
Sep 30, 2025
Balyasny Asset Management LP
1.35M
2.67%
+1.35M
--
Sep 30, 2025
Scotia Capital Inc.
1.28M
2.52%
-14.10K
-1.09%
Sep 30, 2025
Great Point Partners, LLC
1.20M
2.37%
+1.20M
--
Sep 30, 2025
Ally Bridge Group NY LLC
915.00K
1.81%
+915.00K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
